drugset / Trial / NCT02198170
A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to assess the influence of simultaneous CYP3A4 and p-glycoprotein inhibition on lenvatinib pharmacokinetics following a single oral dose of 5 mg lenvatinib.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketoconazole | Small molecule | 400 mg | Oral |
| Subject | Lenvatinib | Small molecule | 5 mg | Oral |
Indications
No indication recorded.